日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cost-Effectiveness of a High-Concentration (179 mg) Capsaicin Patch for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland

在苏格兰,高浓度(179毫克)辣椒素贴剂治疗周围神经性疼痛患者的成本效益分析

Freitas, Rita; van Keep, Marjolijn; Kandaswamy, Prashanth; Prüfert, Anja; Ager, Miranda; Eerdekens, Marielle

Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension

血管内超声肾脏去神经术治疗难治性高血压患者的成本效益分析

Taylor, Rod S; Bentley, Anthony; Metcalfe, Kaylie; Lobo, Melvin D; Kirtane, Ajay J; Azizi, Michel; Clark, Christopher; Murphy, Kieran; Boer, Jennifer H; van Keep, Marjolijn; Ta, An Thu; Barman, Neil C; Schwab, Garrett; Akehurst, Ron; Schmieder, Roland E

Correction: Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension

更正:血管内超声肾脏去神经术治疗难治性高血压患者的成本效益分析

Taylor, Rod S; Bentley, Anthony; Metcalfe, Kaylie; Lobo, Melvin D; Kirtane, Ajay J; Azizi, Michel; Clark, Christopher; Murphy, Kieran; Boer, Jennifer H; van Keep, Marjolijn; Ta, An Thu; Barman, Neil C; Schwab, Garrett; Akehurst, Ron; Schmieder, Roland E

Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE's subscription-style payment model

解决新型抗菌药物市场失灵问题的最新进展:从NICE的订阅式支付模式中汲取经验

Schurer, Marieke; Patel, Renu; van Keep, Marjolijn; Horgan, Jake; Matthijsse, Suzette; Madin-Warburton, Matthew

Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective

从英国医疗保健角度评估度伐利尤单抗治疗不可切除的III期非小细胞肺癌的成本效益:4年生存率更新和模型验证

Dunlop, Will; van Keep, Marjolijn; Elroy, Peter; Perez, Ignacio Diaz; Ouwens, Mario J N M; Sarbajna, Tina; Zhang, Yiduo; Greystoke, Alastair

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

英国使用司库奇尤单抗治疗活动性强直性脊柱炎的成本效益分析

Emery, Paul; Van Keep, Marjolijn; Beard, Steve; Graham, Chris; Miles, LaStella; Jugl, Steffen Marc; Gunda, Praveen; Halliday, Anna; Marzo-Ortega, Helena